FEBOXA is a xanthine oxidase inhibitor used for long-term uric acid control in patients with chronic gout. It effectively lowers blood uric acid levels and prevents its crystallisation in joints and soft tissues.
Recommended for:
Patients diagnosed with gout
Chronic hyperuricemia
Prevention of gout attacks and complications (tophi, kidney stones)
Gout
Hyperuricemia due to chronic conditions
Prevention of urate deposition in joints and soft tissues
FEBOXA is taken orally once daily, with or without food. The dosage is prescribed by a doctor based on the uric acid level and clinical status.
Hypersensitivity to febuxostat
Severe liver impairment
Patients with ischemic heart disease or heart failure (without monitoring)
Elevated liver enzymes
Headache, nausea
Rash or allergic skin reactions
Initial gout flare-up during therapy